Please ensure Javascript is enabled for purposes of website accessibility

Inovio Pharmaceuticals' Zika Vaccine Takes a Big Step Forward

By Keith Speights - May 17, 2016 at 4:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There's good news for the biotech's Zika virus vaccine efforts from non-human primate testing.

Inovio Pharmaceuticals (INO -3.35%) is steadily advancing its development of a potential Zika virus vaccine.

In February, the biotech announced positive results from testing of its Zika vaccine in mice. On May 16, Inovio took one step further in its quest to make it to market. The company reported that testing of its GLS-5700 vaccine for the Zika virus induced "robust" antibody and T cell responses in monkeys. This is probably the most important step for Inovio yet in its effort to develop the world's first Zika vaccine.

It's in the DNA

Make no mistake -- Inovio's earlier testing with mice was a big deal. The protein-coding portions of mouse and human genomes are around 85% identical. Especially because GLS-5700 is a DNA-based vaccine, the good results from testing with mice were meaningful.

But testing with non-human primates like monkeys is an even bigger deal. Humans and monkeys share around 93% of DNA. In Inovio's test, two doses of the Zika vaccine were administered to monkeys. All of the vaccinated monkeys showed specific antibodies in their blood. In addition, researchers found robust T cell responses in the animals.

What does all of this really mean? The results suggested that GLS-5700 could indeed prevent infection by the Zika virus. Antibodies are key in preventing infection. T cells can kill cells that harbor the Zika virus. The presence of both antibodies and broad T cell responses shows promise that Inovio's vaccine could ultimately prove to be effective.

Top banana

The important thing for investors to take away from Inovio's latest announcement is that the small biotech remains in the driver's seat in the race to develop a Zika virus vaccine. Inovio will now be able to move forward with testing in humans later this year. No other company appears to be that far along.

Sanofi (SNY -5.01%) announced in February that it plans to develop a Zika virus vaccine. The French drugmaker already has vaccines on the market for Yellow Fever, Japanese Encephalitis, and Dengue. The company hopes that its Dengue vaccine could be leveraged quickly to also tackle Zika, because the two viruses belong to the same family. Unlike Inovio, though, Sanofi has not yet announced any pre-clinical testing results.

Another large pharmaceutical company could also be in the hunt. GlaxoSmithKline (GSK -0.55%) announced in January that it was evaluating whether its vaccine technology could be used to prevent infection by the Zika virus. Glaxo indicated that it planned to rapidly finish feasibility studies to determine if its vaccines might be effective for the Zika virus. However, the big drugmaker hasn't provided any updates since the January announcement.

The World Health Organization lists several other organizations working on Zika virus vaccines. Only two of them -- Inovio and Indian biotech Bharat -- had pre-clinical work in progress as of March. Bharat chairman Krishna Ella stated earlier this year that it would probably be 10 years before his company's Zika vaccine made it to market.

More bars to clear

Inovio's latest news is encouraging, but there's still a long way to go. The company will begin phase 1 human clinical testing this year. If all goes well, Inovio could then proceed to phase 2 testing. It's possible that the company could seek regulatory approval following phase 2 instead of after phase 3, as is usually the case. Either way, though, we're still at least several years away from seeing GLS-5700 hit the market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (-3.35%) $0.06
Sanofi Stock Quote
Sanofi
SNY
$50.03 (-5.01%) $-2.64
GSK Stock Quote
GSK
GSK
$43.53 (-0.55%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.